Lytix Biopharma
Dr. Currie has over 30 years of drug development experience in both pharmaceutical and biotechnology companies, having held senior leadership roles at Dynavax, Regeneron Pharmaceuticals, Sepracor Inc., PDL Biopharma and Gilead Sciences. Most recently, he was Chief Development Officer of Tolerion Inc. Dr. Currie has successfully led drug development programs and has held key roles in the development of 8 approved drugs.
Dr. Currie holds a PhD from Aston University in the UK.
This person is not in any teams
This person is not in any offices
Lytix Biopharma
A clinical-stage biotech company developing proprietary oncolytic peptides as a novel immune therapy to fight cancer.